Overview
News
Salaries
Products
People
Growth
Offices
Financials

Funding and backers

Team
5
UK accounts · Feb 2026 · +25% in a year
Backers
3
Seedcamp, Episode 1 Ventures
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Feb 4, 2019 Founded per the company register
Tractionpublic signals, read monthly
Web presence
top 0.75%
of 133.2M domains by links, Common Crawl
Registers and programsofficial lists and records that name the company
Legal entity SUPERCEDE LTD Companies House
Registered 4 Feb 2019
Backed byfrom the funds' portfolios and accelerator catalogs
Similar startupsby what they do, their industry and backers
The Intelligence LayerFor Modern Insurance. Powering decision-making across Life, Disability, Health, and Annuities Insurance and…
Turn digital assets into productive underwriting capital. Resolvr earns institutional-grade, genuinely uncorrelated reinsurance yield…
Konduit is the structured exchange for MGAs to find fronting paper, reinsurance capacity, or both. AI-native infrastructure connecting US…
Boost InsuranceFounded 2017
Boost Insurance is a New York technology company founded in 2017 that supplies insurance infrastructure as a service. Its platform gives…
BestowSeries D $120M · 16 mo ago • Founded 2016 • 201-500 employees • 24 roles
Bestow is an insurance technology company headquartered in Dallas, Texas, and founded in 2016. The company provides a comprehensive…
KASKOFounded 2015 • 11-50 employees
KASKO InsurTech & Beyond. Solving challenges across today’s & tomorrow’s insurance value chain — from strategy to delivery.

Overview

Supercede is the leading reinsurtech platform, streamlining reinsurance with advanced data management and deal-making tools for superior outcomes.

News

News bioworld.com 1 year ago
Supercede's SPCD-4-79 demonstrates preclinical efficacy in DIO mice
Supercede Therapeutics Inc. has released preclinical efficacy data on its small-molecule inhibitor of the Activin receptor type II (ACTRII) to treat obesity. Supercede's lead candidate, SPCD-4-79, is an orally bioavailable, low-molecular-weight compound t
Read more
Report

Offices

Where the company hires and what each office is for
Cities
2
Hiring now
0
Countries
1
Loading the map
Headquarters Builds here Office with open vacancies No open vacancies right now Tap a pin for the office
Cleckheaton United Kingdom
HQ
London United Kingdom
Regional office
User Policy
68 King William Street, London, EC4N 7HR, United Kingdom
company site